A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer

The goal of this clinical study is to learn more about the study drug sacituzumab govitecan-hziy (SG) given at an alternative dose and schedule, in participants with triple-negative breast cancer (TNBC). The primary objectives of this study are to assess the safety and tolerability of SG given at alternate dose and schedule, to assess the effect on objective response rate (ORR) and progression-free survival (PFS).

Trial Details

NCT ID
NCT06926920
Phase
PHASE1 / PHASE2
Sponsor
Gilead Sciences
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • Sacituzumab Govitecan-hziy (SG)
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Atlanta, Georgia, United States|33.749,-84.38798
  • Westwood, Kansas, United States|39.04056,-94.6169
  • St Louis, Missouri, United States|38.62727,-90.19789
  • Germantown, Tennessee, United States|35.08676,-89.81009

Key Eligibility Criteria

  • Individuals assigned male or female at birth, 18 years of age or older, able to understand and give written informed consent.
  • Histologically or cytologically locally confirmed TNBC.
  • Phase 1: Individuals with unresectable, locally advanced or metastatic TNBC who are refractory to or relapsed after at least one prior standard-of-…
  • Phase 2: Individuals with unresectable, locally advanced or metastatic TNBC who have not received previous systemic therapy for advanced disease.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →